» Articles » PMID: 10960076

ADP is Not an Agonist at P2X(1) Receptors: Evidence for Separate Receptors Stimulated by ATP and ADP on Human Platelets

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2000 Aug 26
PMID 10960076
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

ADP, an important agonist in thrombosis and haemostasis, has been reported to activate platelets via three receptors, P2X(1), P2Y(1) and P2T(AC). Given the low potency of ADP at P2X(1) receptors and recognized contamination of commercial samples of adenosine nucleotides, we have re-examined the activation of P2X(1) receptors by ADP following HPLC and enzymatic purification. Native P2X(1) receptor currents in megakaryocytes were activated by alpha, beta-meATP (10 microM) and commercial samples of ADP (10 microM), but not by purified ADP (10 - 100 microM). Purified ADP (up to 1 mM) was also inactive at recombinant human P2X(1) receptors expressed in Xenopus oocytes. Purification did not modify the ability of ADP to activate P2Y receptors coupled to Ca(2+) mobilization in rat megakaryocytes. In human platelets, P2X(1) and P2Y receptor-mediated [Ca(2+)](i) responses were distinguished by their different kinetics at 13 degrees C. In 1 mM Ca(2+) saline, alpha,beta-meATP (10 microM) and commercial ADP (40 microM) activated a rapid [Ca(2+)](i) increase (lag time < or =0.5 s) through the activation of P2X(1) receptors. Hexokinase treatment of ADP shifted the lag time by approximately 2 s, indicating loss of the P2X(1) receptor-mediated response. A revised scheme is proposed for physiological activation of P2 receptors in human platelets. ATP stimulates P2X(1) receptors, whereas ADP is a selective agonist at metabotropic (P2Y(1) and P2T(AC)) receptors.

Citing Articles

Ultra-high-throughput Ca assay in platelets to distinguish ITAM-linked and G-protein-coupled receptor activation.

Fernandez D, Provenzale I, Cheung H, van Groningen J, Tullemans B, Veninga A iScience. 2022; 25(1):103718.

PMID: 35072010 PMC: 8762394. DOI: 10.1016/j.isci.2021.103718.


Studies on the role of alpha 7 nicotinic acetylcholine receptors in K562 cell proliferation and signaling.

Onder Narin G, Aydin B, Cabadak H Mol Biol Rep. 2021; 48(6):5045-5055.

PMID: 34143396 DOI: 10.1007/s11033-021-06498-4.


Pharmacological and genetic characterisation of the canine P2X4 receptor.

Sophocleous R, Berg T, Finol-Urdaneta R, Sluyter V, Keshiya S, Bell L Br J Pharmacol. 2020; 177(12):2812-2829.

PMID: 32017039 PMC: 7236074. DOI: 10.1111/bph.15009.


P2Y receptor modulation of ADP-evoked intracellular Ca signalling in THP-1 human monocytic cells.

Micklewright J, Layhadi J, Fountain S Br J Pharmacol. 2018; 175(12):2483-2491.

PMID: 29574692 PMC: 5980558. DOI: 10.1111/bph.14218.


Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets.

Hsia C, Jayakumar T, Sheu J, Tsao S, Velusamy M, Hsia C Molecules. 2018; 23(2).

PMID: 29470443 PMC: 6017231. DOI: 10.3390/molecules23020477.


References
1.
Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P . Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104(12):1731-7. PMC: 409888. DOI: 10.1172/JCI8399. View

2.
Hechler B, Leon C, Vial C, VIGNE P, Frelin C, Cazenave J . The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood. 1998; 92(1):152-9. View

3.
Lewis C, Gitterman D, Schluter H, Evans R . Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol. 2000; 129(1):124-30. PMC: 1621118. DOI: 10.1038/sj.bjp.0702993. View

4.
Boeynaems J, Communi D, Savi P, Herbert J . P2Y receptors: in the middle of the road. Trends Pharmacol Sci. 2000; 21(1):1-3. DOI: 10.1016/s0165-6147(99)01415-7. View

5.
Holmsen H, Weiss H . Secretable storage pools in platelets. Annu Rev Med. 1979; 30:119-34. DOI: 10.1146/annurev.me.30.020179.001003. View